AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Argenica Therapeutics Ltd

0.255

0.000

Volume:7.01K

Turnover:1.79K

Market Cap:32.76M

PE:-3.36

High:0.255

Open:0.255

Low:0.255

Close:0.255

52wk High:0.885

52wk Low:0.190

Shares:128.46M

Float Shares:91.53M

Volume Ratio:0.15

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.076

EPS(LYR):-0.056

ROE:-117.81%

ROA:-61.45%

PB:9.51

PE(LYR):-4.54

Loading ...

Overview Company News Filings

Argenica Therapeutics And 2 Other ASX Penny Stocks Worth Watching

Simply Wall St.

We're Hopeful That Argenica Therapeutics (ASX:AGN) Will Use Its Cash Wisely

Simply Wall St.

BRIEF-Argenica Therapeutics Says Dianne Angus To Step Down As Non-Executive Chair

Argenica Therapeutics' Non-Executive Chair to Step Down

MT Newswires Live

Argenica Therapeutics Ltd - Dianne Angus to Step Down as Non-Executive Chair

THOMSON REUTERS

Argenica Therapeutics Ltd-Non-Executive Chair Resignation

THOMSON REUTERS

Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys

MT Newswires Live

BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition

Argenica Therapeutics Ltd-Non-Executive Director Retirement

THOMSON REUTERS

New Results From Argenica Therapeutics' ARG-007 Second Phase Trial Show 'Encouraging' Signs, Euroz Hartleys Says

MT Newswires Live

Argenica Therapeutics ARG-007 Phase 2 Trial Shows Strong Safety, Efficacy in High-Risk Group, Euroz Hartleys Says

MT Newswires Live

BRIEF-Argenica Therapeutics Seeks Trading Halt

Argenica Therapeutics - Seeks Trading Halt Pending Announcement on Phase 2 Arg-007 Stroke Trial Results

THOMSON REUTERS

Argenica Therapeutics Ltd - FY Loss Attributable a$7.2 Mln

THOMSON REUTERS

Argenica Therapeutics - FY Revenues From Ordinary Activities a$3.7 Mln

THOMSON REUTERS

Argenica Therapeutics Receives Full Clinical Hold Letter from FDA Regarding Investigational New Drug Application

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AGN.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGN.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AGN.AU\",,,,,undefined,":{"symbol":"AGN.AU","market":"AU","secType":"STK","nameCN":"Argenica Therapeutics Ltd","latestPrice":0.255,"timestamp":1771564320000,"preClose":0.255,"halted":0,"volume":7010,"delay":0,"changeRate":0,"nameEN":"Argenica Therapeutics Ltd","floatShares":91529130,"shares":128456712,"eps":-0.076,"marketStatus":"Market Closed","change":0,"latestTime":"02-20 16:12:00 AEDT","open":0.255,"high":0.255,"low":0.255,"amount":1788,"amplitude":0,"askPrice":0.26,"askSize":25600,"bidPrice":0.255,"bidSize":5370,"shortable":3,"etf":0,"ttmEps":-0.076,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771801200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.255,"openAndCloseTimeList":[[1771542000000,1771563600000]],"volumeRatio":0.15196975373003535,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AGN.AU\",,,,,undefined,":{"symbol":"AGN.AU","floatShares":91529130,"roa":"-61.45%","roe":"-117.81%","lyrEps":-0.056226,"volumeRatio":0.15196975373003535,"shares":128456712,"dividePrice":0,"high":0.255,"amplitude":0,"preClose":0.255,"low":0.255,"week52Low":0.19,"pbRate":"9.51","psRate":"32.54","week52High":0.885,"institutionHeld":0,"latestPrice":0.255,"committee":-0.653213,"eps":-0.076,"divideRate":0,"volume":7010,"delay":0,"ttmEps":-0.076,"open":0.255,"prevYearClose":0.295,"prevWeekClose":0.26,"prevMonthClose":0.28,"prevQuarterClose":0.295,"fiveDayClose":0.26,"twentyDayClose":0.26,"sixtyDayClose":0.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGN.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGN.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGN.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609323739","title":"Argenica Therapeutics And 2 Other ASX Penny Stocks Worth Watching","url":"https://stock-news.laohu8.com/highlight/detail?id=2609323739","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609323739?lang=en_us&edition=fundamental","pubTime":"2026-02-05 10:05","pubTimestamp":1770257155,"startTime":"0","endTime":"0","summary":"As the Australian market opens slightly lower today, influenced by global tech sector challenges and cautious investor sentiment, attention turns to opportunities that might be overlooked in more stable times. Penny stocks, often associated with smaller or newer companies, continue to hold potential for those willing to explore beyond established names. These stocks can offer both affordability and growth potential when backed by strong financials; let's examine a few that stand out in the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/argenica-therapeutics-and-2-other-asx-penny-stocks-worth-wat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/argenica-therapeutics-and-2-other-asx-penny-stocks-worth-wat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DSK.AU","BK7128","MXI.AU","BK7062","AGN.AU","SSM.AU","PPS.AU","BK7143","AEF.AU","SKS.AU","BK7055","BK7023","BK7045","VRS.AU","IGL.AU","LENZ","BK7104","BK7506","MTO.AU","BK7077","VLS.AU","BK7050","BK4539","BK7016","BK7096","BK7503","BK4007","WAF.AU","BK4139","SNS.AU"],"gpt_icon":0},{"id":"2600097120","title":"We're Hopeful That Argenica Therapeutics (ASX:AGN) Will Use Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2600097120","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600097120?lang=en_us&edition=fundamental","pubTime":"2026-01-03 08:05","pubTimestamp":1767398745,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-agn/argenica-therapeutics-shares/news/were-hopeful-that-argenica-therapeutics-asxagn-will-use-its-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-agn/argenica-therapeutics-shares/news/were-hopeful-that-argenica-therapeutics-asxagn-will-use-its-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGN.AU","BK7096","AGN"],"gpt_icon":0},{"id":"2595277456","title":"BRIEF-Argenica Therapeutics Says Dianne Angus To Step Down As Non-Executive Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2595277456","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595277456?lang=en_us&edition=fundamental","pubTime":"2025-12-29 09:13","pubTimestamp":1766970794,"startTime":"0","endTime":"0","summary":"BRIEF-Argenica Therapeutics Says Dianne Angus To Step Down As Non-Executive ChairDec 29 (Reuters) - Argenica Therapeutics Ltd AGN.AX:NON-EXECUTIVE CHAIR RESIGNATIONDIANNE ANGUS TO STEP DOWN AS NON-EXECUTIVE CHAIRFurther company coverage: AGN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUEYTK8B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2595939272","title":"Argenica Therapeutics' Non-Executive Chair to Step Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2595939272","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595939272?lang=en_us&edition=fundamental","pubTime":"2025-12-29 08:18","pubTimestamp":1766967538,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  said Dianne Angus has notified its board of her decision to step down as non-executive chair, effective by the end of December, according to a Monday Australian bourse filing.The company said it has started the process to appoint a new chair with experience in global business development and strategic partnering.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","BK7096","AGN.AU","LENZ","BK4539"],"gpt_icon":0},{"id":"2595279748","title":"Argenica Therapeutics Ltd - Dianne Angus to Step Down as Non-Executive Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2595279748","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595279748?lang=en_us&edition=fundamental","pubTime":"2025-12-29 05:27","pubTimestamp":1766957236,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nTUEYTK8B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2595279743","title":"Argenica Therapeutics Ltd-Non-Executive Chair Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2595279743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595279743?lang=en_us&edition=fundamental","pubTime":"2025-12-29 05:27","pubTimestamp":1766957236,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nTUEYTK8B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2590192524","title":"Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2590192524","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590192524?lang=en_us&edition=fundamental","pubTime":"2025-12-12 12:03","pubTimestamp":1765512212,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics'  artificial intelligence-driven reanalysis of its phase 2 stroke trial provide compelling evidence of ARG-007's clinically and commercially meaningful benefit in patients with severe stroke, said Euroz Hartleys in a Thursday note.The research firm said that the phase 2 trial has effectively served its purpose: to characterize the drug's activity and identify the patients most likely to benefit.Euroz Hartleys believes that the totality of evidence is more than sufficient to justify advancing into a targeted phase 2b trial enriched for patients most likely to respond, thereby maximizing the probability of success.Euroz Hartleys maintained its speculative buy rating on AGN with a price target of AU$1.30.Argenica Therapeutics' shares fell past 3% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4007","BK4539","AGN.AU","BK7096"],"gpt_icon":0},{"id":"2588507442","title":"BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588507442","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588507442?lang=en_us&edition=fundamental","pubTime":"2025-12-04 11:05","pubTimestamp":1764817526,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Argenica Therapeutics jumps on meeting FDA condition** Shares of Australia's Argenica Therapeutics AGN.AX surge as much as 34.1% to A$0.295, their highest since November 3** Biotech f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nL6N3XA06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2582496253","title":"Argenica Therapeutics Ltd-Non-Executive Director Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2582496253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582496253?lang=en_us&edition=fundamental","pubTime":"2025-11-12 13:49","pubTimestamp":1762926574,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUE4DZW6N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2575334275","title":"New Results From Argenica Therapeutics' ARG-007 Second Phase Trial Show 'Encouraging' Signs, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2575334275","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575334275?lang=en_us&edition=fundamental","pubTime":"2025-10-15 11:00","pubTimestamp":1760497239,"startTime":"0","endTime":"0","summary":"Latest results from Argenica Therapeutics' (ASX:AGN) second phase trial of neuroprotective drug candidate ARG-007 in acute ischemic stroke showed \"encouraging\" signs of functional improvement across c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","BK4007","LENZ","AGN.AU","BK7096"],"gpt_icon":0},{"id":"2564299713","title":"Argenica Therapeutics ARG-007 Phase 2 Trial Shows Strong Safety, Efficacy in High-Risk Group, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2564299713","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564299713?lang=en_us&edition=fundamental","pubTime":"2025-09-04 15:25","pubTimestamp":1756970704,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  phase 2 trial of ARG-007 showed strong safety and a meaningful efficacy signal in a key high-risk subgroup, materially de-risking the program and supporting partnering potential, Euroz Hartleys said in a note on Thursday.The company shared phase 2 results showing ARG-007 was safe but did not reduce infarct volume overall in acute ischemic stroke patients.It further added that, in a pre-specified subgroup with slow collateral blood flow, which includes about 30% of participants and represents a third of large vessel occlusion strokes, ARG-007 reduced brain injury by 15%.The firm shared that despite missing broader efficacy goals, ARG-007 showed a meaningful effect in a pre-specified high-risk subgroup and has a strong safety profile supporting a planned phase 2 trial before moving to phase 3.The firm has issued a speculative buy recommendation for Argenica Therapeutics with a per-share target price of AU$1.40, which is currently under review.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK7096","BK4139","AGN.AU","BK4539","BK4007"],"gpt_icon":0},{"id":"2564868323","title":"BRIEF-Argenica Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2564868323","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564868323?lang=en_us&edition=fundamental","pubTime":"2025-09-01 07:02","pubTimestamp":1756681355,"startTime":"0","endTime":"0","summary":"BRIEF-Argenica Therapeutics Seeks Trading Halt Sept 1 (Reuters) - Argenica Therapeutics Ltd AGN.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PHASE 2 ARG-007  STROKE TRIAL RESULTSFurther company coverage: AGN.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nFWN3UN002:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2564683288","title":"Argenica Therapeutics - Seeks Trading Halt Pending Announcement on Phase 2 Arg-007  Stroke Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2564683288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564683288?lang=en_us&edition=fundamental","pubTime":"2025-09-01 07:02","pubTimestamp":1756681334,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nFWN3UN002:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2562608845","title":"Argenica Therapeutics Ltd -  FY Loss Attributable a$7.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562608845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562608845?lang=en_us&edition=fundamental","pubTime":"2025-08-28 15:06","pubTimestamp":1756364771,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UK011:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AGN.AU"],"gpt_icon":0},{"id":"2562088437","title":"Argenica Therapeutics - FY Revenues From Ordinary Activities a$3.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562088437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562088437?lang=en_us&edition=fundamental","pubTime":"2025-08-28 15:06","pubTimestamp":1756364771,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UK011:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGN.AU","BK7096"],"gpt_icon":0},{"id":"2559632936","title":"Argenica Therapeutics Receives Full Clinical Hold Letter from FDA Regarding Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2559632936","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559632936?lang=en_us&edition=fundamental","pubTime":"2025-08-14 11:50","pubTimestamp":1755143439,"startTime":"0","endTime":"0","summary":"Argenica Therapeutics  received a full clinical hold letter from the US Food and Drug Administration  on the reasons for the imposed clinical hold and the information required to lift the hold regarding its investigational new drug application, enable clinical trials of the ARG-007 drug candidate in acute ischaemic stroke in the US, according to a Thursday Australian bourse filing.The regulator requested additional information to ensure that the proposed trial dosing for a US trial can be achieved safely in humans, and the firm plans to use its phase two acute ischaemic stroke trial safety data, which will be available in September, as part of its response.The FDA also requested Argenica to conduct three additional in vitro cell culture studies with clinical research organizations to address identified gaps in data. It also asked the firm to include more detail on the phase one data in the investigational brochure.The firm's shares fell 1% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK7096","BK4539","BK4139","AGN.AU","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}